Takeda Pharmaceutical (TAK) Non-Current Assets (2017 - 2026)

Takeda Pharmaceutical's Non-Current Assets history runs 10 years deep, the most recent figure standing at $79.2 billion for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 3.04% year-over-year to $79.2 billion in Q1 2026; TTM through Mar 2026 was $79.2 billion, a 3.04% increase from a year earlier, with the FY2026 full-year figure at $82.5 billion, up 7.18% from the prior year.
• Non-Current Assets slipped to $79.2 billion in Q1 2026 per TAK's latest filing, from $79.9 billion in the prior quarter.
• Across five years, Non-Current Assets topped out at $91.1 billion in Q1 2022 and bottomed at $76.9 billion in Q1 2025.
• The 5-year median for Non-Current Assets is $81.3 billion (2024), against an average of $82.8 billion.
• Across the five-year window, Non-Current Assets fell 14.12% in 2022 and increased 3.33% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $77.2 billion in 2022, then advanced by 3.33% to $79.8 billion in 2023, then increased by 1.83% to $81.3 billion in 2024, then fell by 1.7% to $79.9 billion in 2025, then fell by 0.84% to $79.2 billion in 2026.
• Per Business Quant, the three latest TAK Non-Current Assets figures stand at $79.2 billion (Q1 2026), $79.9 billion (Q4 2025), and $78.4 billion (Q3 2025).